Metrics to compare | IVAA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIVAAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −2.5x | −0.2x | |
PEG Ratio | −0.04 | −0.03 | 0.00 | |
Price/Book | 12.7x | 0.4x | 2.6x | |
Price / LTM Sales | 305.0x | 8.8x | 2.7x | |
Upside (Analyst Target) | 214.8% | 246.9% | 72.2% | |
Fair Value Upside | Unlock | 23.9% | 12.4% | Unlock |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.